RESEARCH - Anti-CCP antibody and RF concentrations predict greater disease activity in men with RA

[Guest guest]

Ann Rheum Dis. 2010 May 3. [Epub ahead of print]

Anti-CCP antibody and rheumatoid factor concentrations predict greater

disease activity in men with rheumatoid arthritis.

Miriovsky BJ, Michaud K, Thiele GM, O'Dell JR, Cannon GW, Kerr G,

s JS, D, Caplan L, Reimold A, Hooker R, Mikuls TR.

1Medicine, Omaha VAMC and the Nebraska Arthritis Outcomes Research

Center, Omaha, Nebraska, USA.

Abstract

OBJECTIVE: To examine associations of anti-cyclic citrullinated

peptide (aCCP) antibody and rheumatoid factor (RF) concentrations with

future disease activity in men with rheumatoid arthritis (RA).

METHODS: Outcome measures were examined in male US veterans with RA

and included (1) proportion of observations in remission (disease

activity score (DAS28) </=2.6); (2) remission for >/=3 consecutive

months; and (3) area under the curve (AUC) for DAS28. The associations

of autoantibody concentration (per 100 unit increments) with outcomes

were examined using multivariate regression.

RESULTS: 826 men with RA were included in the analysis; the mean (SD)

age was 65 (10.5) years and follow-up was for 2.6 (1.3) years. Most

were aCCP (75%) and RF (80%) positive. After multivariate adjustment,

aCCP (OR 0.93; 95% CI 0.89 to 0.96) and RF concentrations (OR 0.92;

95% CI 0.90 to 0.94) were associated with a lower odds of remission, a

lower proportion of observation in remission (p=0.017 and p=0.002,

respectively) and greater AUC DAS28 (p=0.092 and p=0.007,

respectively). Among patients with discordant autoantibody status,

higher concentrations of both aCCP and RF trended towards an inverse

association with remission (OR 0.93; 95% CI 0.83 to 1.05 and OR 0.80;

95% CI 0.59 to 1.10, respectively).

CONCLUSIONS: Higher aCCP concentrations (particularly in RF-positive

patients) are associated with increased disease activity in US

veterans with RA, indicating that aCCP concentration is predictive of

future disease outcomes in men.

PMID: 20439294

http://www.ncbi.nlm.nih.gov/pubmed/20439294

Not an MD